Clinical trials: Dry AMD, open to volunteers
Age-Related Macular Degeneration
Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD).
- Trial name
- OMEGA-AMD (NCT05465252)
- Testing
- Krill Oil, Olive Oil
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Dry Age-related Macular Degeneration, Macular Degeneration, Dry
Observation of the Natural Course of Age-related Macular Degeneration
This research will study natural course of dry AMD in Chinese population, screen fundus imaging indicators for patients with Chinese dry AMD, describe the clinical features of Chinese patients with dry AMD, and obtain a…
- Trial name
- NCT05418231
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI)
Study to Detect Dendritic Cell Recruitment in Human Retina
The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of…
- Conditions
- Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI), Alzheimer Disease
- Trial name
- ICG-002 (NCT06872658)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MindImmune Therapeutics, Inc.
Dry Age-Related Macular Degeneration, Geographic Atrophy
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Background: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots.
- Trial name
- NCT04339764
- Testing
- iPSC-derived RPE/PLGA transplantation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Eye Institute (NEI)
Maculopathy
AVIGA3 (Cohort 2.0)
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central…
- Trial name
- AVIGA3 (NCT07255859)
- Testing
- Amsler Grid, AVIGA
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- Tan Tock Seng Hospital
Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)
Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD
This is a parallel, randomized, open-label, controlled study to evaluate the efficacy and safety of oral EG-301 in patients with intermediate non-exudative (dry) age-related macular degeneration (dAMD).
- Trial name
- NCT05170048
- Testing
- EG-301, AREDS2 supplements
- Volunteers
- 90 people
- Sponsor
- Evergreen Therapeutics, Inc.
Dry Age-related Macular Degeneration
Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma
The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular…
- Trial name
- CORD-IV (NCT05706896)
- Testing
- Intravitreal injection of CB-PRP
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Geographic Atrophy
Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy
This is AGX-08's safety, tolerability, and efficacy in Geographic Atrophy first-in-human study. This trial is meant to evaluate the safety and efficacy of AGX-08 in Geographic Atrophy patients.
- Trial name
- NCT07602127
- Testing
- AGX-08-L, AGX-08-H, AGX-08-S
- Volunteers
- 24 people
- Sponsor
- Zhongmou Therapeutics
Dry Age-related Macular Degeneration
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
- Trial name
- NCT07770828
- Testing
- OCU410
- Where
- 3 sites in United States
- Volunteers
- 237 people
- Sponsor
- Ocugen
Dry Age-related Macular Degeneration, Vision Impairment and Blindness
Vision Improvement for Legally Blind Dry AMD Patients
This retrospective observational study is intended to assess the feasibility of using a nonsignificant risk device for vision improvement for legally blind dry AMD patients.
- Trial name
- NCT04875234
- Testing
- Clear-K Low Vision Aid Treatment
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
Dry Age-related Macular Degeneration
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
- Trial name
- NCT04627428
- Testing
- RPESC-RPE-4W
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Luxa Biotechnology, LLC
Dry Age-related Macular Degeneration
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with…
- Trial name
- NCT06351605
- Testing
- Valeda® Light Delivery System
- Where
- 6 sites in United States, Norway
- Volunteers
- 500 people
- Sponsor
- LumiThera, Inc.
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years.
- Trial name
- Pre-GAIN (NCT07144137)
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Complement Therapeutics
Age-Related Macular Degeneration
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of…
- Trial name
- NCT03178149
- Testing
- ASP7317, tacrolimus, trimethoprim-sulfamethoxazole
- Where
- 20 sites in United States
- Volunteers
- 42 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Macular Degeneration, Senile, Laser Burn of Retina
Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration
Prospective, randomized, controlled, longitudinal, interventional multicentric study involving patients with reticular pseudodrusen secondary to AMD.
- Conditions
- Macular Degeneration, Senile, Laser Burn of Retina, Macular Degeneration Intermediate, Macular Degeneration, Dry
- Trial name
- PASCAL-RPD (NCT04847635)
- Testing
- Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Ospedale San Raffaele
Photobiomodulation, Age-Related Macular Degeneration
Photobiomodulation for Dry Age Related Macula Degeneration
The study will investigate the effect of photobiomodulation treatment on the risk of developing late age related macula degeneration (AMD) in the study eye in patients with wet AMD in the fellow eye.
- Trial name
- NCT05507840
- Testing
- Valeda machine
- Volunteers
- 121 people
- Sponsor
- Oslo University Hospital
Dry AMD, Geographic Atrophy
Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence.
- Conditions
- Dry AMD, Geographic Atrophy, Healhty
- Trial name
- VIRETTA (NCT07433088)
- Testing
- Object recognition and selection task
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Streetlab
Age Related Macular Degeneration
Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants
Age-related macular degeneration (AMD) affects 2 million people in France and is the main cause of irreversible blindness in France. All patients initially have an early form of the disease.
- Trial name
- SURViVOR (NCT04697095)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Hospices Civils de Lyon
Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
This is a Phase 1/2 study, multi-center, dose-escalation interventional study of BS01 in subjects with GA secondary to dry AMD. Part 1 is an open label dose-escalation study; Part 2 is a dose-expansion study with dose(s) selected…
- Trial name
- NCT07158775
- Testing
- BS01
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bionic Sight LLC
Retinal Disease, Macular Degeneration
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
- Conditions
- Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy
- Trial name
- NCT06394232
- Testing
- Eyecyte-RPE™
- Where
- 3 sites in India
- Volunteers
- 54 people
- Sponsor
- Eyestem Research Pvt. Ltd.